Longevity Medical Institute publishes review on stem cells and inflammaging

Longevity Medical Institute says a new peer-reviewed review in the Journal of Clinical and Biomedical Advances synthesizes evidence that mesenchymal stem cells can reduce chronic inflammation tied to aging and age-related disease. The paper could help shape future research on broad-spectrum approaches to healthspan and regenerative medicine.

Why it matters: - Chronic inflammation, or inflammaging, is increasingly viewed as a core driver of biological aging and many age-related diseases. - The review suggests mesenchymal stem cells, or MSCs, may influence multiple inflammatory pathways at once instead of targeting a single molecule. - That approach could matter for conditions linked to aging, including cardiovascular disease, metabolic disorders, neurodegenerative disease, musculoskeletal degeneration and frailty.

What happened: - Longevity Medical Institute announced the publication of a peer-reviewed systematic review on MSCs and chronic inflammation. - The paper is titled "Mesenchymal Stromal Cells as Modulators of Chronic Inflammation, Inflammaging, and Age-Related Disease: A Systematic Review." - The review was published in the Journal of Clinical and Biomedical Advances, ISSN 3066-716X. - The paper lists DOI 10.63620/MKJCBA.2026.1059. - The institute is based in San José del Cabo, Baja California Sur, Mexico. - The announcement was dated July 19, 2026.

The details: - The review examined preclinical and clinical evidence on MSC therapy and its effects on inflammatory biomarkers and immune signaling pathways tied to aging and chronic disease. - The analysis followed PRISMA 2020 guidelines. - The authors searched PubMed, Embase, Scopus, Web of Science and the Cochrane Library. - Across the studies reviewed, MSC therapy reduced pro-inflammatory markers including IL-6, TNF-α, IL-1β and C-reactive protein. - MSC therapy also increased anti-inflammatory mediators such as IL-10. - The review linked these immunomodulatory effects with improved clinical outcomes across multiple disease models and patient populations. - The publication describes MSCs as acting through several complementary mechanisms, including regulation of innate and adaptive immune responses, suppression of excessive inflammatory signaling, promotion of regulatory immune cells, shifting macrophages toward tissue-repair phenotypes and secretion of bioactive factors that support tissue healing and immune balance. - Longevity Medical Institute said the review adds to its peer-reviewed research on mesenchymal stromal cells in regenerative medicine. - The institute said recent publications have examined MSC therapy for knee osteoarthritis, diabetic foot ulcers, COVID-19 and overall safety across a broad range of clinical indications. - The institute says its clinical offerings include advanced laboratory testing, full-body MRI, cardiac imaging, precision health assessments, regenerative medicine, cellular therapies, hyperbaric oxygen therapy, peptides and personalized longevity programs. - Longevity Medical Institute also says its multidisciplinary team focuses on patient care and scientific research through peer-reviewed publications and clinical innovation. - More information is available in the company's announcement. - The institute also provided social links for LinkedIn, Instagram, Facebook, YouTube and X.

Between the lines: - The review frames MSCs as a broad immunomodulatory tool rather than a single-target anti-inflammatory treatment. - That distinction matters because age-related diseases often share overlapping inflammatory biology. - The publication also positions Longevity Medical Institute as a research-driven clinic trying to build credibility through peer-reviewed work.

What's next: - The review is likely to support more clinical investigation into MSCs for aging-related inflammation and disease. - Longevity Medical Institute signaled that it will continue publishing on MSC safety and clinical use across additional indications. - The paper may also influence how researchers think about therapies aimed at healthspan, not just individual diseases.

The bottom line: - Longevity Medical Institute is betting that MSCs could become part of a broader strategy to slow or blunt the inflammatory biology tied to aging.